{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T06:53:10Z","timestamp":1791010390976,"version":"4.1.0"},"reference-count":95,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.critrevonc.2026.105268","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T16:14:23Z","timestamp":1773159263000},"page":"105268","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Trispecific antibodies: From challenges to integration in cancer therapy"],"prefix":"10.1016","volume":"222","author":[{"given":"Ahmed Reda","family":"Bahr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim Saleh","family":"Alawadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila Mohamed","family":"Akr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basant Atef","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaber H.","family":"Jaradat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yara Mohamed","family":"El-said","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Hamdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.critrevonc.2026.105268_bib1","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.3390\/pharmaceutics15102402","article-title":"Fc-engineered therapeutic antibodies: recent advances and future directions","volume":"15","author":"Abdeldaim","year":"2023","journal-title":"Pharmaceutics"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105268_bib2","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1182\/bloodadvances.2024014986","article-title":"TP53 mutations are associated with CD19\u2212 relapse and inferior outcomes after blinatumomab in adults with ALL","volume":"9","author":"Aldoss","year":"2025","journal-title":"Blood Adv."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105268_bib3","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3390\/life11060465","article-title":"BiTEs, DARTS, BiKEs and TriKEs\u2014are antibody based therapies changing the future treatment of AML?","volume":"11","author":"Allen","year":"2021","journal-title":"Life"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105268_bib4","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2024.2394229","article-title":"Developability considerations for bispecific and multispecific antibodies","volume":"16","author":"Amash","year":"2024","journal-title":"mAbs"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105268_bib5","doi-asserted-by":"crossref","first-page":"5319","DOI":"10.3390\/ijms26115319","article-title":"From molecular precision to clinical practice: a comprehensive review of bispecific and trispecific antibodies in hematologic malignancies","volume":"26","author":"Amoozgar","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105268_bib6","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1038\/s41375-020-01065-5","article-title":"A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells","volume":"35","author":"Arvindam","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2026.105268_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107762","article-title":"Bi\/tri-specific antibodies (HN-Fc-CD16 and HN-Fc-IL-15-CD16) cross-linking natural killer (NK)-CD16 and Newcastle Disease Virus (NDV)-HN, enhanced NK activation for cancer immunotherapy","volume":"96","author":"Bahrololoumi Shapourabadi","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.critrevonc.2026.105268_bib8","doi-asserted-by":"crossref","first-page":"A1180","DOI":"10.1136\/jitc-2024-SITC2024.1060","article-title":"1060 DF9001, an EGFR targeted immune engager, stimulates innate and adaptive anti-tumor immunity with a distinctive safety profile","author":"Bigelow","year":"2024","journal-title":"Regul. Young.. Invest. Award Abstr."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105268_bib9","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1080\/13543784.2025.2511180","article-title":"Clinical development of tri-specific antibodies for immune-oncology","volume":"34","author":"Cao","year":"2025","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105268_bib10","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/s43018-024-00821-1","article-title":"ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells","volume":"5","author":"Carretero-Iglesia","year":"2024","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105268_bib11","doi-asserted-by":"crossref","unstructured":"Characterization of JNJ-79635322, a Novel BCMAxGPRC5DxCD3 T-Cell Redirecting Trispecific Antibody, for the Treatment of Multiple Myeloma | Blood | American Society of Hematology. (n.d.). Retrieved January 16, 2026, from \u3008https:\/\/ashpublications.org\/blood\/article\/142\/Supplement%201\/456\/500284\/Characterization-of-JNJ-79635322-a-Novel\u3009.","DOI":"10.1182\/blood-2023-174941"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105268_bib12","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.7150\/thno.72594","article-title":"Antibody-based drug delivery systems for cancer therapy: mechanisms, challenges, and prospects","volume":"12","author":"Chen","year":"2022","journal-title":"Theranostics"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105268_bib13","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2217\/imt-2023-0256","article-title":"A trispecific antibody induces potent tumor-directed T-cell activation and antitumor activity by CD3\/CD28 co-engagement","volume":"16","author":"Chen","year":"2024","journal-title":"Immunotherapy"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105268_bib14","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1039\/D1BM01218E","article-title":"A novel anti-tumor\/anti-tumor-associated fibroblast\/anti-mPEG tri-specific antibody to maximize the efficacy of mPEGylated nanomedicines against fibroblast-rich solid tumor","volume":"10","author":"Chen","year":"2022","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.critrevonc.2026.105268_bib15","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.2147\/IJN.S301237","article-title":"Active tumoral\/tumor environmental dual-targeting by non-covalently arming with trispecific antibodies or dual-bispecific antibodies on docetaxel-loaded mPEGylated nanocarriers to enhance chemotherapeutic efficacy and minimize systemic toxicity","volume":"16","author":"Cheng","year":"2021","journal-title":"Int. J. Nanomed."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105268_bib16","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.it.2007.07.011","article-title":"Immunogenicity of protein therapeutics","volume":"28","author":"De Groot","year":"2007","journal-title":"Trends Immunol."},{"key":"10.1016\/j.critrevonc.2026.105268_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1029214","article-title":"Activation of distinct antiviral T-cell immunity: a comparison of bi- and trispecific T-cell engager antibodies with a chimeric antigen receptor targeting HBV envelope proteins","volume":"13","author":"Debelec-Butuner","year":"2022","journal-title":"Front. Immunol."},{"issue":"S3","key":"10.1016\/j.critrevonc.2026.105268_bib18","doi-asserted-by":"crossref","DOI":"10.1097\/01.HS9.0000967944.12345.32","article-title":"S258: IPH6501 is a first-in-class tetraspecific antibody-based natural killer cell engager therapeutic developed for the treatment of B-cell non-hodgkin\u2019s lymphomas","volume":"7","author":"Demaria","year":"2023","journal-title":"HemaSphere"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105268_bib19","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s40364-025-00764-4","article-title":"Revolutionizing oncology: the role of Artificial Intelligence (AI) as an antibody design, and optimization tools","volume":"13","author":"Dewaker","year":"2025","journal-title":"Biomark. Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105268_bib20","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2022.2115213","article-title":"Development of T-cell engagers selective for cells co-expressing two antigens","volume":"14","author":"Dicara","year":"2022","journal-title":"mAbs"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105268_bib21","doi-asserted-by":"crossref","first-page":"445","DOI":"10.4161\/mabs.20776","article-title":"Molecular engineering of antibodies for therapeutic and diagnostic purposes","volume":"4","author":"Ducancel","year":"2012","journal-title":"mAbs"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105268_bib22","doi-asserted-by":"crossref","first-page":"5632","DOI":"10.3390\/ijms22115632","article-title":"Principles and current clinical landscape of multispecific antibodies against cancer","volume":"22","author":"Elshiaty","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105268_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.111698","article-title":"An innovative antibody fusion protein targeting PD-L1, VEGF and TGF-\u03b2 with enhanced antitumor efficacies","volume":"130","author":"Fan","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.critrevonc.2026.105268_bib24","unstructured":"Fc Silenced Antibodies. (n.d.). Retrieved \u3008https:\/\/ichor.bio\/fc-silenced-antibodies\u3009."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105268_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0061953","article-title":"Crystal structure of an Anti-Ang2 CrossFab demonstrates complete structural and functional integrity of the variable domain","volume":"8","author":"Fenn","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.critrevonc.2026.105268_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.biotechadv.2023.108201","article-title":"Modulating antibody effector functions by Fc glycoengineering","volume":"67","author":"Garc\u00eda-Alija","year":"2023","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.critrevonc.2026.105268_bib27","doi-asserted-by":"crossref","first-page":"A633","DOI":"10.1136\/jitc-2025-SITC2025.0554","article-title":"554 Pharmacokinetics (PK) and pharmacodynamics (PD) of ISB 2001, a BCMAxCD38xCD3 trispecific antibody, in TRIgnite-1, the first-in-human (FIH) phase 1 study in relapsed\/refractory multiple myeloma (RRMM)","author":"Garton","year":"2025","journal-title":"Regul. Young.. Invest. Award Abstr."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105268_bib28","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1038\/s41587-022-01626-2","article-title":"Control of acute myeloid leukemia by a trifunctional NKp46-CD16a-NK cell engager targeting CD123","volume":"41","author":"Gauthier","year":"2023","journal-title":"Nat. Biotechnol."},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2026.105268_bib29","doi-asserted-by":"crossref","first-page":"10699","DOI":"10.1182\/blood-2022-164753","article-title":"Affibody-based BCMA x CD16 dual engagers for activation of NK cells towards multiple myeloma","volume":"140","author":"Giang","year":"2022","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105268_bib30","doi-asserted-by":"crossref","first-page":"879","DOI":"10.3390\/cells13100879","article-title":"Pre-clinical assessment of SAR442257, a CD38\/CD3xCD28 trispecific T cell engager in treatment of relapsed\/refractory multiple myeloma","volume":"13","author":"Grab","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.critrevonc.2026.105268_bib31","unstructured":"GTB-3550 Tri-Specific Killer Engager (TriKE\u00ae) for High Risk Hematological Malignancies. (n.d.). Retrieved \u3008https:\/\/clinicaltrials.gov\/study\/NCT03214666\u3009."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105268_bib32","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1158\/0008-5472.CAN-14-1670","article-title":"Four-in-one antibodies have superior cancer inhibitory activity against EGFR, HER2, HER3, and VEGF through disruption of HER\/MET crosstalk","volume":"75","author":"Hu","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105268_bib33","unstructured":"Ichnos Glenmark Innovation (IGI) Receives U.S. FDA Fast Track Designation for ISB 2001 for Relapsed\/Refractory Multiple Myeloma\u2014IGI. (n.d.). Retrieved November 21, 2025, from \u3008https:\/\/iginnovate.com\/2025\/05\/03\/ichnos-glenmark-innovation-igi-receives-usfda-fasttrack-designation-for-isb-2001-for-relapsed-refractory-multiple-myeloma\/\u3009."},{"key":"10.1016\/j.critrevonc.2026.105268_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1533059","article-title":"A trispecific antibody targeting EGFR\/cMET\/VEGF-A demonstrates multiple mechanisms of action to inhibit wild-type and mutant NSCLC animal models","volume":"15","author":"Jin","year":"2025","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105268_bib35","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41392-021-00868-x","article-title":"Emerging new therapeutic antibody derivatives for cancer treatment","volume":"7","author":"Jin","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105268_bib36","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/biot.201400052","article-title":"Avoiding antibody aggregation during processing: establishing hold times","volume":"9","author":"Joshi","year":"2014","journal-title":"Biotechnol. J."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105268_bib37","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3390\/antib14020035","article-title":"A comprehensive review about the use of monoclonal antibodies in cancer therapy","volume":"14","author":"Justiz-Vaillant","year":"2025","journal-title":"Antibodies"},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2026.105268_bib38","doi-asserted-by":"crossref","first-page":"7097","DOI":"10.1182\/blood-2022-169072","article-title":"High Ex Vivo Response Rates to CD38\/CD28xCD3 Trispecific T Cell Engager in Patients Relapsed after Anti-CD38 and Anti-BCMA Targeted Immunotherapies","volume":"140","author":"Keller","year":"2022","journal-title":"Blood"},{"issue":"7_ement","key":"10.1016\/j.critrevonc.2026.105268_bib39","doi-asserted-by":"crossref","first-page":"5680","DOI":"10.1158\/1538-7445.AM2023-5680","article-title":"Abstract 5680: Tetra-specific antibody GNC-039: guidance and navigation control (GNC) molecule development for treatment of EGFRvIII+ malignancies","volume":"83","author":"Khalili","year":"2023","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105268_bib40","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s40259-025-00752-y","article-title":"Conditionally activatable antibody platforms: mechanisms, modalities, and clinical translation potential","volume":"40","author":"Kim","year":"2026","journal-title":"BioDrugs"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105268_bib41","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3892\/or.2023.8649","article-title":"Cancer therapeutic trispecific antibodies recruiting both T and natural killer cells to cancer cells","volume":"50","author":"Kimura","year":"2023","journal-title":"Oncol. Rep."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105268_bib42","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1158\/2643-3230.BCD-23-0228","article-title":"Emerging strategies for the prevention of immune toxicities associated with T cell\u2013engaging cancer therapies","volume":"5","author":"Kowalski","year":"2024","journal-title":"Blood Cancer Discov."},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2026.105268_bib43","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1182\/blood-2022-168739","article-title":"Characterization of JNJ-80948543, a Novel CD79bxCD20xCD3 Trispecific T-cell redirecting antibody for the treatment of B-cell non-hodgkin lymphoma","volume":"140","author":"Kuchnio","year":"2022","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105268_bib44","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105268_bib45","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1111\/ddg.15502","article-title":"Dermatological toxicities of talquetamab, a new bispecific antibody: case series and literature review","volume":"22","author":"Mansilla-Polo","year":"2024","journal-title":"JDDG J. der Dtsch. Dermatol. Ges."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105268_bib46","doi-asserted-by":"crossref","first-page":"6645","DOI":"10.1038\/ncomms7645","article-title":"A plug-and-play approach to antibody-based therapeutics via a chemoselective dual click strategy","volume":"6","author":"Maruani","year":"2015","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105268_bib47","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1158\/1078-0432.CCR-20-3392","article-title":"Preclinical characterization of HPN536, a trispecific, T-cell\u2013activating protein construct for the treatment of mesothelin-expressing solid tumors","volume":"27","author":"Molloy","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105268_bib48","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/d41573-021-00079-7","article-title":"FDA approves 100th monoclonal antibody product","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"41","key":"10.1016\/j.critrevonc.2026.105268_bib49","doi-asserted-by":"crossref","first-page":"10706","DOI":"10.1002\/anie.201209979","article-title":"Combating multidrug-resistant bacteria: current strategies for the discovery of novel antibacterials","volume":"52","author":"O\u2019Connell","year":"2013","journal-title":"Angew. Chem. Int. Ed."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105268_bib50","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.humimm.2022.01.004","article-title":"Designing of a bispecific antibody against SARS-CoV-2 spike glycoprotein targeting human entry receptors DPP4 and ACE2","volume":"83","author":"Ojha","year":"2022","journal-title":"Hum. Immunol."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105268_bib51","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41573-022-00501-8","article-title":"Avidity in antibody effector functions and biotherapeutic drug design","volume":"21","author":"Oostindie","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.critrevonc.2026.105268_bib52","first-page":"1","article-title":"Current Development of Monoclonal Antibodies in Cancer Therapy","volume":"214","author":"Parakh","year":"2020"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105268_bib53","first-page":"269","article-title":"Novel tri-specific tribodies induce strong T cell activation and anti-tumor effects in vitro and in vivo","volume":"41","author":"Passariello","year":"2022","journal-title":"J. Exp. Clinic. Cancer Res. CR"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105268_bib54","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41568-024-00690-x","article-title":"Cancer therapy with antibodies","volume":"24","author":"Paul","year":"2024","journal-title":"Nat. Rev. Cancer"},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2026.105268_bib55","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1182\/blood-2022-159353","article-title":"ISB 2001, a first-in-class trispecific BCMA and CD38 T cell engager designed to overcome mechanisms of escape from treatments for multiple myeloma by targeting two antigens","volume":"140","author":"Pihlgren","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2026.105268_bib56","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2022019451","article-title":"Pre-clinical characterization of ISB 1342, a CD38xCD3 T-cell engager for relapsed\/refractory multiple myeloma","author":"Pouleau","year":"2023","journal-title":"Blood J."},{"key":"10.1016\/j.critrevonc.2026.105268_bib57","first-page":"277","article-title":"Optimal structural designs of trispecific antibodies to enhance therapeutic efficacy in solid tumors and hematological malignancies","volume":"2930","author":"Qi","year":"2025"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105268_bib58","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/j.apsb.2024.03.027","article-title":"Stepping forward: T-cell redirecting bispecific antibodies in cancer therapy","volume":"14","author":"Qin","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105268_bib59","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s40164-025-00667-y","article-title":"Immunotherapy in breast cancer: current landscape and emerging trends","volume":"14","author":"Ran","year":"2025","journal-title":"Exp. Hematol. & Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105268_bib60","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/protein\/9.7.617","article-title":"Knobs-into-holes\u2019 engineering of antibody CH 3 domains for heavy chain heterodimerization","volume":"9","author":"Ridgway","year":"1996","journal-title":"Protein Eng. Des. Sel."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105268_bib61","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/s41423-024-01176-4","article-title":"Bridging the gap with multispecific immune cell engagers in cancer and infectious diseases","volume":"21","author":"Rolin","year":"2024","journal-title":"Cell. & Mol. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105268_bib62","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s10020-018-0051-4","article-title":"Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics","volume":"24","author":"Runcie","year":"2018","journal-title":"Mol. Med."},{"key":"10.1016\/j.critrevonc.2026.105268_bib63","unstructured":"SAR443216 Engages HER2 With Manageable Toxicity in Advanced HER2+ Solid Tumors. (n.d.). Retrieved \u3008https:\/\/www.onclive.com\/view\/sar443216-engages-her2-with-manageable-toxicity-in-advanced-her2-solid-tumors\u3009."},{"issue":"27","key":"10.1016\/j.critrevonc.2026.105268_bib64","doi-asserted-by":"crossref","first-page":"11187","DOI":"10.1073\/pnas.1019002108","article-title":"Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies","volume":"108","author":"Schaefer","year":"2011","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"7\u20138","key":"10.1016\/j.critrevonc.2026.105268_bib65","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1515\/hsz-2023-0329","article-title":"Better safe than sorry: dual targeting antibodies for cancer immunotherapy","volume":"405","author":"Schoenfeld","year":"2024","journal-title":"Biol. Chem."},{"issue":"7900","key":"10.1016\/j.critrevonc.2026.105268_bib66","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/s41586-022-04439-0","article-title":"A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells","volume":"603","author":"Seung","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105268_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112424","article-title":"IMT030122, A novel engineered EpCAM\/CD3\/4-1BB tri-specific antibody, enhances T-cell recruitment and demonstrates anti-tumor activity in mouse models of colorectal cancer","volume":"137","author":"Shen","year":"2024","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105268_bib68","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1128\/CMR.00030-10","article-title":"Challenges of antibacterial discovery","volume":"24","author":"Silver","year":"2011","journal-title":"Clin. Microbiol. Rev."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105268_bib69","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3233\/HAB-1999-9105","article-title":"Development of a trispecific antibody conjugate that directs two distinct tumor-associated antigens to CD64 on myeloid effector cells","volume":"9","author":"Somasundaram","year":"1999","journal-title":"Hum. Antibodies"},{"issue":"16_","key":"10.1016\/j.critrevonc.2026.105268_bib70","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1200\/JCO.2024.42.16_suppl.2573","article-title":"Effect of MP0317, a FAP x CD40 DARPin, on safety profile and tumor-localized CD40 activation in a phase 1 study in patients with advanced solid tumors","volume":"42","author":"Steeghs","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105268_bib71","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/s41467-018-03335-4","article-title":"Rational design of a trispecific antibody targeting the HIV-1 Env with elevated anti-viral activity","volume":"9","author":"Steinhardt","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105268_bib72","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1356666","article-title":"Therapeutic approaches to enhance natural killer cell cytotoxicity","volume":"15","author":"Stenger","year":"2024","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105268_bib73","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1182\/blood-2005-05-2177","article-title":"A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo","volume":"107","author":"Strandmann","year":"2006","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105268_bib74","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010140","article-title":"Leveraging T cell co-stimulation for enhanced therapeutic efficacy of trispecific antibodies targeting prostate cancer","volume":"13","author":"Sun","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105268_bib75","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2021.1967714","article-title":"Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins","volume":"13","author":"Surowka","year":"2021","journal-title":"mAbs"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105268_bib76","first-page":"1","article-title":"Challenges and solutions for the downstream purification of therapeutic proteins","volume":"7","author":"Tang","year":"2024","journal-title":"Antib. Ther."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105268_bib77","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202206912","article-title":"Overcoming the On-target toxicity in antibody-mediated therapies via an indirect active targeting strategy","volume":"10","author":"Tang","year":"2023","journal-title":"Adv. Sci."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105268_bib78","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13045-023-01482-w","article-title":"Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies","volume":"16","author":"Tapia-Galisteo","year":"2023","journal-title":"J. Hematol. & Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105268_bib79","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13045-023-01482-w","article-title":"Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies","volume":"16","author":"Tapia-Galisteo","year":"2023","journal-title":"J. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105268_bib80","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.7150\/thno.81494","article-title":"When three is not a crowd: trispecific antibodies for enhanced cancer immunotherapy","volume":"13","author":"Tapia-Galisteo","year":"2023","journal-title":"Theranostics"},{"issue":"56","key":"10.1016\/j.critrevonc.2026.105268_bib81","doi-asserted-by":"crossref","first-page":"7434","DOI":"10.1039\/c4cc02354d","article-title":"A prospective antibacterial for drug-resistant pathogens: a dual warhead amphiphile designed to track interactions and kill pathogenic bacteria by membrane damage and cellular DNA cleavage","volume":"50","author":"Thiyagarajan","year":"2014","journal-title":"Chem. Commun."},{"issue":"16_","key":"10.1016\/j.critrevonc.2026.105268_bib82","doi-asserted-by":"crossref","first-page":"7505","DOI":"10.1200\/JCO.2025.43.16_suppl.7505","article-title":"First-in-human study of JNJ-79635322 (JNJ-5322), a novel, next-generation trispecific antibody (TsAb), in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): Initial phase 1 results","volume":"43","author":"Van De Donk","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105268_bib83","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s11684-021-0835-8","article-title":"Preclinical characterization and comparison between CD3\/CD19 bispecific and novel CD3\/CD19\/CD20 trispecific antibodies against B-cell acute lymphoblastic leukemia: targeted immunotherapy for acute lymphoblastic leukemia","volume":"16","author":"Wang","year":"2022","journal-title":"Front. Med."},{"issue":"16_","key":"10.1016\/j.critrevonc.2026.105268_bib84","doi-asserted-by":"crossref","first-page":"TPS2668","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS2668","article-title":"GNC-038, a tetra-specific antibody, in patients with R\/R non-Hodgkin lymphoma or acute lymphoblastic leukemia: a phase 1 study design and rationale","volume":"41","author":"Wang","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105268_bib85","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.2004661","article-title":"Engineering of a trispecific tumor-targeted immunotherapy incorporating 4-1BB co-stimulation and PD-L1 blockade","volume":"10","author":"Warmuth","year":"2021","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105268_bib86","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2208697","article-title":"Engaging natural killer cells for cancer therapy via NKG2D, CD16A and other receptors","volume":"15","author":"Whalen","year":"2023","journal-title":"mAbs"},{"issue":"20","key":"10.1016\/j.critrevonc.2026.105268_bib87","doi-asserted-by":"crossref","first-page":"6110","DOI":"10.1046\/j.1432-1327.2000.01702.x","article-title":"Thioredoxin reductase two modes of catalysis have evolved","volume":"267","author":"Williams","year":"2000","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.critrevonc.2026.105268_bib88","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ymeth.2018.08.010","article-title":"Building blocks for bispecific and trispecific antibodies","volume":"154","author":"Wu","year":"2019","journal-title":"Methods"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105268_bib89","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s43018-019-0004-z","article-title":"Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation","volume":"1","author":"Wu","year":"2019","journal-title":"Nat. Cancer"},{"issue":"7\u20138","key":"10.1016\/j.critrevonc.2026.105268_bib90","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1093\/protein\/gzy007","article-title":"Generation of orthogonal Fab-based trispecific antibody formats","volume":"31","author":"Wu","year":"2018","journal-title":"Protein Eng. Des. Sel."},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2026.105268_bib91","doi-asserted-by":"crossref","first-page":"3381.2","DOI":"10.1182\/blood-2024-200737","volume":"144","author":"Xu","year":"2024","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105268_bib92","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/imm.13636","article-title":"Trispecific antibodies for cancer immunotherapy","volume":"169","author":"Yao","year":"2023","journal-title":"Immunology"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105268_bib93","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/imm.13636","article-title":"Trispecific antibodies for cancer immunotherapy","volume":"169","author":"Yao","year":"2023","journal-title":"Immunology"},{"key":"10.1016\/j.critrevonc.2026.105268_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.115719","article-title":"A novel B7-H4\/CD3\/CD28 trispecific antibody with the SpyTag-SpyCatcher technology suppresses the growth of colorectal cancer","volume":"167","author":"Zhang","year":"2025","journal-title":"Int. Immunopharmacol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105268_bib95","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.70046","article-title":"Natural killer cell engagers: from bi-specific to tri-specific and tetra-specific engagers for enhanced cancer immunotherapy","volume":"14","author":"Zhu","year":"2024","journal-title":"Clin. Transl. Med."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826001551?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826001551?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T06:42:16Z","timestamp":1778481736000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826001551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":95,"alternative-id":["S1040842826001551"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105268","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trispecific antibodies: From challenges to integration in cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105268","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105268"}}